Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction

Next Previous
Trial Profile

Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Heart failure; Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms STEP-HFpEF
  • Sponsors Novo Nordisk

Most Recent Events

  • 19 Sep 2024 According to a Novo Nordisk media release, company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy (semaglutide 2.4 mg) label in the European Union (EU), based on the results from the STEP HFpEF and STEP HFpEF-DM trials.
  • 05 Sep 2024 According to a The Heart Failure Society of America (HFSA) media release, data from this trial to be presented at Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), Sept 27-30, at the Georgia World Congress Center and the new Signia by Hilton Atlanta in Atlanta, GA.
  • 30 Aug 2024 Results of post-hoc pooled, participant-level analysis of patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction (HFpEF) from the SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM randomized, placebo-controlled trials. published in the Lancet Journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top